Recent Company News

• 07:02 AM ET Oct 20, 2025
  

  Autolus Therapeutics announces first patient dosed in Phase 1 Trial of obecabtagene autoleucel (Obe-Cel) in patients with progressive multiple sclerosis ($1.62, 0.00)

• 02:44 PM ET Oct 17, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 19-Oct

• 09:24 AM ET Oct 16, 2025
  

  Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

• 01:50 PM ET Oct 10, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Oct

• 02:37 PM ET Oct 03, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 5-Oct

• 08:30 AM ET Sep 15, 2025
  

  Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

• 09:13 AM ET Aug 12, 2025
  

  StreetAccount Summary - US Pre-market trading update